Cisplatin-based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer

Cancer Research and Treatment

Volumn 47, Issue 4, 2015, Pages 670-675

  Lee, Yun Gyoo ^a,b   Lee, Eunyoung ^a   Kim, Inho ^a   Lee, Keun Wook ^c   Kim, Tae Min ^a   Lee, Se Hoon ^a   Kim, Dong Wan ^a   Heo, Dae Seog ^a  

^a Seoul National University Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Cisplatin; Small cell lung carcinoma; Thromboembolism

Indexed keywords

BELOTECAN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; TOPOTECAN; ANTINEOPLASTIC AGENT;

AGED; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SMALL CELL LUNG CANCER; SMOKING; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPLICATION; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; SMALL CELL LUNG CARCINOMA; TIME FACTOR;

ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMALL CELL LUNG CARCINOMA; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84946710111     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.045     Document Type: Article

References (18)

1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-22.
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-15.
3. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104: 2822-9.
4. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166:458-64.
5. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169-78.
6. Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103: 994-9.
7. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466-73.
8. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30:4416-26.
9. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002;20:4665-72.
10. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530-5.
11. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-7.
12. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-7.
13. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601-8.
14. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021-4.
15. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007;5:2445-52.
16. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19:927-9.
17. Lu CF, Yu HJ, Hou JX, Zhou J. Increased procoagulant activity of red blood cells in the presence of cisplatin. Chin Med J (Engl). 2008;121:1775-80.
18. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol. 1992;8:480-8.